Forward-Looking Statements

Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively “forward-looking statements”). The company cautions that such statements involve risks and uncertainties that may materially affect the company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products, including the approval of Sci-B-Vac® in the U.S., Europe, and Canada following the completion of its recent Phase 3 studies; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the company’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the company, is set forth in the Company’s filings with the Securities and Exchange Commission and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2020, and filed with the Canadian security authorities at sedar.com on March 5, 2020, and may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. The company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Overview of VBI Vaccines

• Leveraging significant immunology expertise to address unmet medical needs in both INFECTIOUS DISEASE and IMMUNO-ONCOLOGY

• Advancing prevention and treatment of HEPATITIS B:
  • *Sci-B-Vac®*: Only trivalent Hepatitis B vaccine; recently completed a Phase III program in the U.S., Europe, and Canada; approved and marketed in Israel
  • *VBI-2601*: Immuno-therapeutic in development in a collaboration with Brii Biosciences for a functional cure for chronic Hepatitis B

• Integrating CYTOMEGALOVIRUS (CMV) EXPERTISE with a proprietary enveloped virus-like particle (eVLP) platform technology to develop next-generation vaccines:
  • *VBI-1901*: GLIOBLASTOMA (GBM) vaccine immunotherapeutic candidate (currently in Phase I/IIa study)
  • *VBI-1501*: Prophylactic CMV vaccine candidate (positive topline Phase I data announced in May 2018)
## VBI Vaccines Pipeline

<table>
<thead>
<tr>
<th>INFECTION DISEASE</th>
<th>PRE-CLINICAL</th>
<th>PHASE I</th>
<th>PHASE II</th>
<th>PHASE III</th>
<th>APPROVED</th>
<th>STATUS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hepatitis B – Prophylaxis</strong></td>
<td>Sci-B-Vac®</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Approved in for use and commercially-available in Israel and Hong Kong</td>
</tr>
<tr>
<td></td>
<td>VLP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis B – Therapeutic</strong></td>
<td>VBI-2601</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Regulatory submissions in U.S., Europe, and Canada expected to begin Q4 2020</td>
</tr>
<tr>
<td></td>
<td>VLP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cytomegalovirus (CMV)</strong></td>
<td>VBI-1501</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Positive Phase I data announced May 2018</td>
</tr>
<tr>
<td></td>
<td>eVLP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Zika</strong></td>
<td>VBI-2501</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Candidate selected</td>
</tr>
<tr>
<td></td>
<td>eVLP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## IMMUNO-ONCOLOGY

<table>
<thead>
<tr>
<th>IMMUNO-ONCOLOGY</th>
<th>PRE-CLINICAL</th>
<th>PHASE I</th>
<th>PHASE II</th>
<th>PHASE III</th>
<th>APPROVED</th>
<th>STATUS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glioblastoma (GBM)</strong></td>
<td>VBI-1901</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Ongoing Phase I/Ila</td>
</tr>
<tr>
<td></td>
<td>eVLP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Expanded immunologic data expected mid-year 2020 and Q4 2020</td>
</tr>
<tr>
<td><strong>Other CMV+ Tumors</strong></td>
<td>VBI-1901</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Preclinical work ongoing</td>
</tr>
<tr>
<td></td>
<td>eVLP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Recent Key Achievements

**JUNE 2019 – MARCH 2020**

<table>
<thead>
<tr>
<th>Month</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 2020</td>
<td>Announcement of 12-month overall survival (OS) and median OS data from Part A of the ongoing Phase I/IIa study of VBI-1901 (GBM)</td>
</tr>
<tr>
<td>March 2020</td>
<td>First patient dosed in Phase IIa portion of ongoing study of VBI-1901 + GSK’s AS01\textsubscript{B} adjuvant system (GBM)</td>
</tr>
<tr>
<td>January 2020</td>
<td>Announcement of positive top-line data from the CONSTANT Phase III study of Sci-B-Vac®</td>
</tr>
<tr>
<td>November 2019</td>
<td>First patient dosed in Phase Ib/Ila study of BRII-179 (VBI-2601) in patients with chronic hepatitis B</td>
</tr>
<tr>
<td>November 2019</td>
<td>Announcement of positive initial Phase I/Ila Part B data of VBI-1901 (GBM) at SNO Annual Meeting</td>
</tr>
<tr>
<td>October 2019</td>
<td>Announcement of late-breaking poster at AASLD’s The Liver Meeting® detailing immunogenicity and safety data from the PROTECT Phase III study of Sci-B-Vac®</td>
</tr>
<tr>
<td>October 2019</td>
<td>Announcement of late-breaking oral presentation at IDWeek 2019™ highlighting detailed seroprotection data from the PROTECT Phase III study of Sci-B-Vac®</td>
</tr>
<tr>
<td>September 2019</td>
<td>Closed Public Offering for gross proceeds of $40.3 million</td>
</tr>
<tr>
<td>September 2019</td>
<td>Announcement of GSK collaboration to evaluate VBI-1901 + GSK’s AS01\textsubscript{B} adjuvant system in additional study arm of ongoing Phase I/Ila study in patients with glioblastoma (GBM)</td>
</tr>
<tr>
<td>July 2019</td>
<td>First patient dosed in Phase IIa portion of ongoing study of VBI-1901 + GM-CSF (GBM)</td>
</tr>
<tr>
<td>June 2019</td>
<td>Announcement of addition to Russell 2000® and 3000® Indexes</td>
</tr>
<tr>
<td>June 2019</td>
<td>Announcement of positive top-line data from the PROTECT Phase III study of Sci-B-Vac®</td>
</tr>
<tr>
<td>June 2019</td>
<td>ASCO presentation of data from Part A of ongoing Phase I/Ila study of VBI-1901 (GBM)</td>
</tr>
</tbody>
</table>
Hepatitis B - Prophylaxis

a. SCI-B-VAC®
Only commercially-available trivalent vaccine containing pre-S1, pre-S2, and S antigens of Hepatitis B virus
# Chronic HBV is a Significant and Increasing Unmet Need in US & EU

There are more than 2,000,000,000 individuals WW with serological evidence of Hepatitis B, of these ~292M are chronic carriers

## U.S.

- CDC estimates that anywhere from \(850,000 – 2.2M\) people in the U.S. are chronically infected with Hepatitis B
- Estimated new cases of Hepatitis B have been increasing since 2012, from roughly 18,800 new cases in 2012 to 21,000 in 2016
- The CDC has determined this increase is largely due to the ongoing opioid epidemic

## Europe

- The European Centre for Disease Prevention and Control (ECDC) estimates that in the EU/EEA ~5M people are chronically infected with Hepatitis B
- Among EU/EEA countries that consistently report, the rate of new cases increased from \(6.7/100,000\) in 2008 to \(10.2/100,000\) in 2017, with UK reporting roughly 62% of all new chronic cases
- The increase in Europe is largely due to the increased population migration and refugee crises – a 2012 study noted the prevalence of HBsAg in the base EU population varied (0.01-0.7%), but the prevalence of HBsAg in the three largest migrant groups in each country was similar, ~4%

Transmission of Chronic Hepatitis B

Chronic Hepatitis B is most commonly transmitted from mother to child (pediatrics) or through nosocomial transmission (i.e., patients exposed in the healthcare setting).

2017 Transmission of Hepatitis B Cases by Acute and Chronic Disease Status (EU/EEA)

- Heterosexual transmission
- Nosocomial*
- Sex between men
- Non-occupational injuries
- Injecting drug use
- Other
- Sexual transmission (not specified)
- Household
- Needle-stick and other occupational exposure
- Blood and blood products
- Mother-to-child transmission
- Haemodialysis
- Organ and tissue

*Nosocomial transmission includes hospitals, nursing homes, psychiatric institutions, and dental services. This category refers mainly to patients exposed through healthcare settings, distinct from “needle-stick and other occupational exposure” which refers to staff.

Source: European Center for Disease Prevention and Control (ECDC) Hepatitis B Annual Epidemiological Report for 2017
HBV Vaccination Rates : U.S.

- In 1991, the ACIP recommended a comprehensive HBV vaccination program: universal vaccination for children and for high-risk populations.

- Despite this recommendation being in place for ~15 years, coverage rates among US adults remains low.

- During 2010-2015, hepatitis B vaccination coverage decreased among all adults aged ≥ 19 years.

- Vaccination rates have remained stable, however, among adults aged ≥ 19 years with chronic liver conditions and among health care providers.

### Reported US Hepatitis B Vaccination Coverage - 2015

<table>
<thead>
<tr>
<th>Category</th>
<th>Coverage Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Otherwise Healthy</strong></td>
<td></td>
</tr>
<tr>
<td>Adults aged ≥ 19 years</td>
<td>24.6%</td>
</tr>
<tr>
<td>Adults aged 19-49 years</td>
<td>32.0%</td>
</tr>
<tr>
<td>Adults age ≥ 50 years</td>
<td>16.5%</td>
</tr>
<tr>
<td><strong>High-Risk</strong></td>
<td></td>
</tr>
<tr>
<td>Chronic Liver Conditions</td>
<td>27.4%</td>
</tr>
<tr>
<td>Diabetics – Age 19-59 years</td>
<td>24.4%</td>
</tr>
<tr>
<td>Diabetics – Age ≥ 60 years</td>
<td>12.6%</td>
</tr>
<tr>
<td>Healthcare Providers ≥ 19 years</td>
<td>64.7%</td>
</tr>
</tbody>
</table>

Source: 2015 CDC Surveillance of Vaccination Coverage Among Adult Populations
HBV Vaccination Rates: Europe

- In 1992, the World Health Assembly recommended the inclusion of Hepatitis B vaccination in all national immunization programs.
- By 2004, the majority of European member states had introduced the vaccine, either as universal infant, universal newborn, or universal adolescent.
- A number of EU member states, however, had not introduced the vaccine into the routine program— all of these were northern European countries.

**RECOMMENDATION FOR HEPATITIS B VACCINATION BY COUNTRY (VENICE II SURVEY)**

- HBV vaccination included in the routine childhood vaccination & recommended for high risk groups incl. healthcare workers (HCWs):
  - 74% of surveyed countries (20/27)
- HBV vaccination only recommended for high-risk groups incl. HCWs:
  - 26% of surveyed countries (7/27)
- Countries not included in VENICE II survey

Despite recommendations, estimated adult HBV vaccine coverage rates vary greatly (e.g. 8% in Denmark, 33% in Germany)

Note: Since this survey, the UK implemented routine childhood vaccination against Hepatitis B (in Aug. 2017)

**Sci-B-Vac® : Importance of Trivalent Conformation**

<table>
<thead>
<tr>
<th>Viral antigens mimicked:</th>
<th>2ND GENERATION VACCINES</th>
<th>SCI-B-VAC®</th>
</tr>
</thead>
<tbody>
<tr>
<td>S Protein</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Pre-S1</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Pre-S2</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adjuvant:</th>
<th>Next-generation Adj. (e.g. TLRs)</th>
<th>Alum</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Derivation:</th>
<th>rDNA yeast</th>
<th>Mammalian cell</th>
</tr>
</thead>
</table>

- Pre-S1 antigen induces key neutralizing antibodies that block virus receptor binding.
- Published data demonstrates that T cell response to pre-S1 and pre-S2 antigens can further boost responses to the S antigens, resulting in a more immunogenic response.
Sci-B-Vac®: Two Phase III Studies to Support Approval in U.S., Europe, and Canada

<table>
<thead>
<tr>
<th>Phase III Study</th>
<th>PROTECT 2-arm safety and immunogenicity study</th>
<th>CONSTANT 4-arm lot-to-lot consistency study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>N size</strong></td>
<td>1,607</td>
<td>2,838</td>
</tr>
<tr>
<td><strong>Age Range</strong></td>
<td>18+ years</td>
<td>18-45 years</td>
</tr>
<tr>
<td><strong>Control Vaccine</strong></td>
<td>Engerix-B® (GSK)</td>
<td>Engerix-B® (GSK)</td>
</tr>
</tbody>
</table>
| **Primary Endpoint(s)** | Based on seroprotection rates (SPR):  
  i. Non-inferiority in adults $\geq$ age 18  
  ii. Superiority in adults $\geq$ age 45 | Consistency of immune response as measured by Geometric Mean Concentration (GMC) of antibodies across three consecutively manufactured lots of Sci-B-Vac® |
| **Secondary Endpoint(s)** | i. Safety and tolerability  
  ii. Non-inferiority of SPR after 2 doses of Sci-B-Vac® vs. 3 doses of Engerix-B® | i. Safety and tolerability  
  ii. Non-inferiority of SPR after 3 doses of Sci-B-Vac® vs. 3 doses of Engerix-B® |
| **Top-Line Data Readout** | June 2019                                  | January 2020                                |
PROTECT Study Subject Disposition

Subjects screened (n=2,472)

Screening failure (n=865, 35%)

Randomized (n=1,607) at 28 clinical study sites in U.S., Europe, and Canada

Engerix-B® (n=811)

Age:
• 18-44 years : 154 (19%)
• 45-64 years : 361 (45%)
• 65+ years : 296 (37%)

Gender:
• Male : 303 (37%)
• Female : 508 (63%)

Withdrew : 42 (5.2%)

Completed study (n=769)

Sci-B-Vac® (n=796)

Age:
• 18-44 years : 145 (18%)
• 45-64 years : 355 (45%)
• 65+ years : 296 (37%)

Gender:
• Male : 315 (40%)
• Female : 481 (60%)

Withdrew : 40 (5.0%)

Completed study (n=756)
Both PROTECT Co-Primary Endpoints Successfully Met

Co-Primary Endpoints at Day 196, 4 weeks post-3rd vaccination:

1. **Non-Inferiority of seroprotection rate (SPR)** achieved in all subjects age 18+

   - **Engerix-B 20µg** 76.5%
   - **Sci-B-Vac 10µg** 91.4%
   - **Diff:** 14.9%
   - **95% CI:** [11.2% to 18.6%]
   - **N:** 723

2. **Statistical and clinical superiority**, as defined in the protocol, achieved in subjects age 45+

   - **Engerix-B 20µg** 73.1%
   - **Sci-B-Vac 10µg** 89.4%
   - **Diff:** 16.4%
   - **95% CI:** [12.2% to 20.7%]
   - **N:** 627

- **Non-inferiority**: If the lower bound of the 95% confidence interval (CI) of the difference between the SPR in the Sci-B-Vac® arm minus the SPR in the Engerix-B® arm is > -5%, Sci-B-Vac® will be declared non-inferior to Engerix-B®
- **Statistical superiority**: If the lower bound of the same 95% CI is greater than 0%, Sci-B-Vac® will be declared statistically superior to Engerix-B®
- **Clinical superiority**: If the lower bound of the same 95% CI is > 5%, Sci-B-Vac® will be declared clinically superior to Engerix-B®
Kinetics of Seroprotection Rates by Age Group

**All Ages (18+)**

- **Engerix-B**: 16.0% at 0 months, 23.9% at 2 months, 27.4% at 6 months, 66.0% at 8 months, 76.5% at 10 months, 89.0% at 12 months.
- **Sci-B-Vac**: 7.7% at 0 months, 51.5% at 2 months, 66.0% at 6 months, 91.4% at 8 months, 89.0% at 10 months, 68.8% at 12 months.

**Ages 18-44**

- **Engerix-B**: 28.8% at 0 months, 37.0% at 2 months, 39.0% at 6 months, 87.2% at 8 months, 97.5% at 12 months.
- **Sci-B-Vac**: 9.6% at 0 months, 76.0% at 2 months, 91.1% at 6 months, 99.2% at 8 months, 87.1% at 12 months.
Seroprotection Rates in Subgroup Populations

SPR of Sci-B-Vac® vs. Engerix-B® was statistically significantly higher in all key subgroup analyses of adults age ≥ 18 years, at Day 196, 4 weeks post-3rd vaccination, including:

- **Diabetes**
  - 58.3% Engerix-B® vs. 83.3% Sci-B-Vac®
  - SPR difference: 25.0%; 95% CI [8.4%, 40.4%]

- **Subjects with a Body Mass Index (BMI) > 30**
  - 68.1% Engerix-B® vs. 89.2% Sci-B-Vac®
  - SPR difference: 21.1%; 95% CI [14.3%, 28.0%]
Anti-HBsAg Titers in Subgroup Populations

5-8x fold higher antibody GMC is maintained for patients who received Sci-B-Vac® vs. Engerix-B® regardless of age, BMI, or diabetes status

<table>
<thead>
<tr>
<th>Age</th>
<th>BMI ≤ 30</th>
<th>BMI &gt;30</th>
<th>Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Ages</td>
<td>6X</td>
<td>5.7X</td>
<td>5.9X</td>
</tr>
<tr>
<td>18-39 y.o.</td>
<td>6X</td>
<td>5.9X</td>
<td>5.4X</td>
</tr>
<tr>
<td>40-49 y.o.</td>
<td>4.4X</td>
<td>6.4X</td>
<td>5.9X</td>
</tr>
<tr>
<td>50-59 y.o.</td>
<td>5.9X</td>
<td>6.9X</td>
<td></td>
</tr>
<tr>
<td>60-69 y.o.</td>
<td>5.1X</td>
<td>8X</td>
<td></td>
</tr>
<tr>
<td>70+ y.o.</td>
<td>6.9X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Error bars = SE; The GMC and SE are calculated based on log10-transformed data, then transformed back to Anti-HBsAg Antibody titer.
Summary of PROTECT Safety Data

OVERALL:

- No safety signals observed in PROTECT
- Sci-B-Vac® safety profile consistent with previous studies and post-marketing use (Israel)
- High rate of completion of vaccinations, 96.8% and 95.2% for Engerix-B® and Sci-B-Vac®, respectively
- Low rate of vaccine discontinuation due to non-serious adverse events (AEs) of 0.4% vs. 0.4% and due to SAEs of 0.2% vs. 0.3% for Engerix-B® and Sci-B-Vac®, respectively

REACTOGENICITY – SOLICITED AEs:

- Higher rates of mild-to-moderate injection site pain, tenderness and myalgia reported by subjects receiving Sci-B-Vac® compared to Engerix-B®
- Reactogenicity symptoms generally resolved without intervention within 1-7 days
- No increase in reactogenicity symptoms over the 3-dose vaccination schedule
Subjects screened (n=4,452)

Screening failure (n=1,614 – 36%)

Randomized (n=2,838) at 32 clinical study sites in U.S., Europe, and Canada

**CONSTANT Study Subject Disposition**

- **Engerix-B® (n=712)**
  - Mean Age (yrs) : 33.4
  - % Male : 40.9%
  - % Female : 59.1%
  - Mean BMI : 25.7
  - Withdrew : 69 (9.7%)
  - Completed Study: n=643

- **Sci-B-Vac® Lot A (n=711)**
  - Mean Age (yrs) : 33.8
  - % Male : 42.6%
  - % Female : 57.4%
  - Mean BMI : 25.9
  - Withdrew : 75 (10.5%)
  - Completed Study: n=636

- **Sci-B-Vac® Lot B (n=709)**
  - Mean Age (yrs) : 32.9
  - % Male : 44.1%
  - % Female : 55.9%
  - Mean BMI : 25.8
  - Withdrew : 72 (10.2%)
  - Completed Study: n=637

- **Sci-B-Vac® Lot C (n=706)**
  - Mean Age (yrs) : 33.9
  - % Male : 41.2%
  - % Female : 58.8%
  - Mean BMI : 26.0
  - Withdrew : 81 (11.5%)
  - Completed Study: n=625
Anti-HBsAg Antibody Titers After 2 & 3 Vaccinations

Antibody GMC achieved with Sci-B-Vac® was more than 7.5x that achieved with Engerix-B® after 2 vaccinations (day 168) and more than 3x after 3 vaccinations (day 196)

CONSTANT Phase 3 Study – Anti-HBsAg Antibody Titers
Subjects Age 18-45

<table>
<thead>
<tr>
<th>Day</th>
<th>Engerix-B®</th>
<th>Sci-B-Vac®: Lot A</th>
<th>Sci-B-Vac®: Lot B</th>
<th>Sci-B-Vac®: Lot C</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>168</td>
<td>15</td>
<td>124</td>
<td>113</td>
<td>120</td>
</tr>
<tr>
<td>196</td>
<td>1,526</td>
<td>5,979</td>
<td>4,855</td>
<td>5,553</td>
</tr>
</tbody>
</table>

100 mIU/mL: Recommended as the optimal protective threshold to ensure persistent immunity

10 mIU/mL: Minimal protective immunity
Kinetics of Seroprotection Rates (SPR) in Younger Adults – Age 18-45 Years

At each time point, day 168 after two vaccinations and day 196 after three vaccinations, the SPR achieved with Sci-B-Vac® was higher than the SPR achieved with Engerix-B®

**CONSTANT Phase 3 Study**
*Subjects Age 18-45*

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Day 168 2 Doses</th>
<th>Day 168 3 Doses</th>
<th>Day 196 2 Doses</th>
<th>Day 196 3 Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Engerix-B® 20µg</td>
<td>51.6%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sci-B-Vac® 10µg</td>
<td></td>
<td>90.4%</td>
<td></td>
<td>99.3%</td>
</tr>
</tbody>
</table>

**PROTECT Phase 3 Study**
*Subjects Age 18-44*

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Day 168 2 Doses</th>
<th>Day 168 3 Doses</th>
<th>Day 196 2 Doses</th>
<th>Day 196 3 Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Engerix-B® 20µg</td>
<td></td>
<td></td>
<td></td>
<td>87.2%</td>
</tr>
<tr>
<td>Sci-B-Vac® 10µg</td>
<td></td>
<td></td>
<td></td>
<td>99.2%</td>
</tr>
</tbody>
</table>

NOTE: SPR defined as percent (%) of subjects with anti-HBsAg titers > 10mIU/mL
## Key Unmet Medical Need and Market Segmentation

<table>
<thead>
<tr>
<th>Target Population</th>
<th>Key Product Attributes Driving Use</th>
<th>Est. Unvaccinated Population</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ADULT POPULATION (AGE 18+)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Young, “Otherwise Healthy”</td>
<td>• Public service sector workers (incl. HCWs)</td>
<td>• Earlier seroprotection</td>
</tr>
<tr>
<td></td>
<td>• Military</td>
<td>• Cost</td>
</tr>
<tr>
<td></td>
<td>• Pre-diabetics</td>
<td></td>
</tr>
<tr>
<td>Older Adults</td>
<td>• Age 45+</td>
<td>• Superior seroprotection rates</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Safety</td>
</tr>
<tr>
<td>Immuno-Compromised/High-Risk</td>
<td>• Diabetics</td>
<td>• Higher seroprotection rates</td>
</tr>
<tr>
<td></td>
<td>• CKD/ESRD patients</td>
<td>• Safety</td>
</tr>
<tr>
<td></td>
<td>• Other high-risk populations</td>
<td></td>
</tr>
<tr>
<td><strong>PEDIATRIC POPULATION (AGE 0-17)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High-risk, Immuno-compromised Newborns</td>
<td><em>Children born:</em></td>
<td>• Higher seroprotection rates</td>
</tr>
<tr>
<td></td>
<td>• with immuno-compromising conditions</td>
<td>• Safety</td>
</tr>
<tr>
<td></td>
<td>(e.g. Thalassemia)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• to HBV-infected mothers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• in high endemic areas</td>
<td></td>
</tr>
</tbody>
</table>

Sources: U.S. Center for Disease Control, U.S. Department of Health and Human Services, European Centre for Disease Prevention and Control, World Health Organization, U.S. Census Population Data
PROTECT/CONSTANT Data Summary & Next Steps

When comparing Sci-B-Vac® at 10µg to Engerix-B® at 20µg, PROTECT and CONSTANT top-line data showed:

- **Higher rates of protection in all adults**, at all time points on a per-visit basis, with statistical and clinical superiority in adults age 45 years and older
- **Higher seroprotection in key immunocompromised populations** including obese individuals, diabetics, and elderly
- **Confirmation of robust immune response elicited with Sci-B-Vac®** – including with respect to both SPR and anti-HBsAg antibody titers – after both two and three vaccinations
- **Lot-to-lot manufacturing consistency**, required as part of the chemistry, manufacturing, and control (CMC) portion of the BLA
- **Clean safety profile** of the vaccine, with no new safety risks identified

Next Steps:

- **Q2 2020**: Pre-BLA discussion expected with FDA
  
  *Subject to outcome of pre-BLA discussion and discussions with other regulatory bodies:*
- **Q4 2020**: Submissions of applications for regulatory approvals in the U.S., Europe, and Canada expected to begin
Hepatitis B - Therapeutic

b. VBI-2601

Potential to contribute to a functional cure by inducing and sustaining broad and effective immunity against chronic Hepatitis B infection
Functional Cure Combination for Hepatitis B

Scientific consensus is that a functional cure is within reach, but will likely be achieved through a combination approach.

A functional cure will likely require the achievement of the below:

1. Drive down hepatitis B virus (HBV) DNA
2. Drive down immuno-suppressive HBV S-antigen
3. Achieve long-term immunologic control

Consensus is building that an immuno-therapeutic would be needed to achieve long-term immunologic control and restore the body’s defense against hepatitis B infection.
VBI-2601 Well Positioned as an Immuno-Therapeutic Component of a Functional Cure for Hepatitis B

VBI-2601 is designed to impact circulating virus (via anti-S immunity – step 7), viral entry (via pre-S1 immunity – step 1), and infected hepatocytes (via T-cell immunity – step 8).

Current NUCs & next-generation therapies impact intracellular steps downstream of transcription (steps 3, 4, & 5).

HBV Life Cycle

1. Attachment / Entry (Pre-S1 immunity or NTCP inhibitors)
2. cccDNA Formation (cccDNA inhibitors)
3. Transcription/Translation (siRNA, Antisense)
4. Reverse Transcription (NUCs)
5. Assembly (Core inhibitors, assembly inhibitors)
6. Secretion
7. Circulation (Anti-HBsAg antibodies)
8. Elimination of Infected Cells (CD8+ T-cell vaccine responses)
Brii Biosciences License & Collaboration Agreement

In December 2018, VBI announced a license and collaboration agreement with Brii Biosciences ("Brii Bio") to develop a functional cure for Hepatitis B

- Under the agreement, VBI and Brii Bio will collaborate in the development of the product candidate through to completion of a proof-of-concept clinical trial, following which, Brii Bio will be responsible for funding all development in the licensed territory – China, Hong Kong, Macau, and Taiwan

- VBI received gross proceeds of $11 million, consisting of a $4M upfront payment and a $7M equity investment at $3.05 per share

- VBI is eligible to receive an additional $117.5 million in potential milestone payments and potential low double-digit royalties on commercial sales in the licensed territory

- VBI will retain all rights outside of the licensed territory with respect to the treatment of hepatitis B
Program Milestones : VBI-2601 (Tx HBV)

- **December 2018**: License and collaboration agreement announced with Brii Biosciences for up to $129M + royalties to develop a functional cure for hepatitis B

- **January 2019**: Initiation of pre-clinical studies

- **Q4 2019**: Initiation of proof-of-concept Phase Ib/IIa study in subjects with chronic hepatitis B

- **H2 2020**: Initial human proof-of-concept Phase Ib/IIa data expected
Enveloped Virus-Like Particle ("eVLP") Vaccine Technology
eVLPs are a 3rd-Generation Class of Synthetic Vaccines

- eVLPs are the same size and structure as enveloped viruses, presenting antigens in their natural state for an improved immune response.
- The foundation of the eVLP Platform is a stable, protein-based core which has the flexibility to express additional vaccine antigens of interest.

Electron Microscopy image of VBI’s CMV eVLPs captured at Scripps Institute.
Two Candidates from eVLP Platform Technology Target CMV-Associated Indications

### Attributes

<table>
<thead>
<tr>
<th>Attributes</th>
<th>VBI-1501</th>
<th>VBI-1901</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present antigen in natural conformation</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>Broadly Reactive Neutralizing Antibodies</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>Polyvalent Immune Response</td>
<td></td>
<td>++</td>
</tr>
<tr>
<td>Potent Th1 Cellular Immunity for Therapeutic Applications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4+</td>
<td>++</td>
<td>+++</td>
</tr>
<tr>
<td>CD8+</td>
<td></td>
<td>++</td>
</tr>
</tbody>
</table>

**Modified gB-G**

**Unmodified gB**

**gb Envelope Antigen**

**pp65 Antigen**
Glioblastoma - VBI-1901

Targeting CMV as a foreign viral antigen approach to Immuno-Oncology (GBM) with a bivalent eVLP expressing two potent CMV antigens – pp65 and gB
Impact and Risks of Cytomegalovirus (CMV)

**ONCOLOGY**

**Solid Tumors:**

- 90%+ of some solid tumors, incl. glioblastomas, breast cancers, and medulloblastomas are CMV+

- CMV is not causative, but does influence disease progression of CMV+ tumors

- In multiple clinical studies, CMV-targeting vaccines have increased overall survival in GBM patients

- Because CMV is so broadly (and differentially) expressed on tumor cells, but not on healthy cells, a potent CMV vaccine has potential to make “cold tumors hot”

- GBM is one of the most aggressive cancers with few therapeutic options and no standard of care in the recurrent setting
GBM Phase I/IIa Clinical Study Design

Two-part, multi-center, open-label, dose-escalation study of VBI-1901 in patients with recurrent glioblastoma (GBM)

**PART A : Dose-Escalation Phase**

*Patient population :*
Recurrent GBM (any # of recurrences)

- **Study Arm 3:**
  - High Dose – 10.0µg + GM-CSF
  - \( N=6 \)
  - Enrollment completed December 2018

- **Study Arm 2:**
  - Intermediate Dose – 2.0µg + GM-CSF
  - \( N=6 \)
  - Enrollment completed September 2018

- **Study Arm 1:**
  - Low Dose – 0.4µg + GM-CSF
  - \( N=6 \)
  - Enrollment completed April 2018

**PART B : Extension Phase**

*Patient population :*
First Recurrent GBM

- **Study Arm 1:**
  - 10.0µg + GM-CSF
  - \( N=10 \)
  - Enrollment initiated July 2019

- **Study Arm 2:**
  - 10.0µg + GSK’s AS01\textsubscript{B} adjuvant system
  - \( N=10 \)
  - Enrollment initiated February 2020

**Outcome Measures : Part A & B**

- **Safety**
- **Immunogenicity :** (1) T-cell immunity (gB, pp65), (2) serum anti-gB antibody titers, (3) other immune correlates and biomarkers
- **Tumor and clinical responses :** Based on MRIs and survival data
- **Quality of life :** Change from baseline
Part A: Safety, Immunologic, and Tumor Responses

SAFETY:

• VBI-1901 was well-tolerated at all doses, with no safety signals observed

• Grade 2, 3, or 4 adverse events occurred in 66%, 22%, and 11% of participants, respectively – none were related to the vaccine immunotherapeutic

IMMUNOGENICITY AND TUMOR RESPONSES:

• Six (6) patients immunologically responded to VBI-1901, with evidence of robust boosting of CMV-specific immune responses against both gB and pp65 antigens

• Three out of six (3/6) patients in the high-dose cohort had evidence of stable disease (SD) by magnetic resonance imaging (MRI), compared to one out of six (1/6) in the low-dose cohort and zero out of six (0/6) in the intermediate-dose cohort
Part A : Clinical Responses

MEDIAN PROGRESSION-FREE SURVIVAL (PFS) :

• Median PFS was longer among vaccine responders (14.5 weeks) vs. vaccine non-responders (6.0 weeks)

OVERALL SURVIVAL (OS) :

• 12-month OS rate in vaccine responders was 83% (n=5/6) vs. 33% among non-responders (n=3/9)\(^1\)

• 6-month OS was 100% among vaccine responders (n=6/6) vs. 63% among non-responders (n=5/8)

MEDIAN OVERALL SURVIVAL (OS) :

• Median OS was longer among vaccine responders (14.0 months) vs. non-responders (7.75 months)\(^1\)

\(^1\)Current commonly-used regimens, including chemotherapy and VEGF-A inhibitors, have demonstrated 12- month OS rates below 50% and median OS of 8-12 months
Tumor Response Data

DATA FROM SNO 2019 POSTER PRESENTATION

Part A : Tumor Responders in High-Dose Cohort

- ~60% reduction seen in Lesion 1
- Lesion 2 appeared after 4.5 months, defined PD per protocol, though patient was clinically stable
- ~60% reduction seen in Lesion 1
- Appearance of Lesion 2 with associated cyst required surgical resection of lesions
- Initial tumor progression later presumed to be pseudo-progression due to subsequent tumor stabilization (atypical of rGBM)

Part B : Available Data

- ~33% reduction in tumor seen to-date
- Stable Disease (SD) based on 2 consecutive scans
VBI-1901 (GBM) : Program Milestones

- **November 2018**: Announcement of initial immunologic data from Part A of the ongoing Phase I/IIa at the Society for Neuro-oncology (SNO) Meeting
- **December 2018**: Completion of enrollment in Part A of the Phase I/IIa
- **June 2019**: Presentation of expanded immunologic data and tumor and clinical responses at ASCO Annual Meeting
- **July 2019**: Initiation of enrollment in Part B of the Phase I/IIa study
- **September 2019**: Announcement of GSK collaboration to clinically evaluate VBI-1901 + GSK’s AS01B adjuvant system in additional study arm of ongoing Phase I/IIa study
- **Q4 2019**: Initial immunologic data from VBI-1901 + GM-CSF Part B and expanded Part A data expected
- **Q1 2020**: Initiation of enrollment in VBI-1901 + GSK’s AS01B study arm expected, subject to FDA acceptance of the amended protocol and investigational site institutional review board approval
- **Mid-year 2020**: Expanded immunologic data and clinical and tumor responses expected from VBI-1901 + GM-CSF study arm
CMV eVLP Vaccine – VBI-1501

eVLP vaccine candidate potently expresses a modified-form of the gB antigen, which is functionally differentiated from other gB approaches.
Impact and Risks of Cytomegalovirus (CMV)

**Birth Defects (Congenital Infection):**

- Congenital CMV is a leading cause of birth defects worldwide
- A first exposure during pregnancy can lead to death, blindness, deafness, and developmental delays of the newborn
- ~30,000 infants are born in U.S. with CMV annually
- 5,000+ will develop permanent impairments (more impacted births than Downs Syndrome)
- Direct economic costs of CMV infection exceeds $3.0B per year in U.S.
- No approved treatment or prevention
- ~$1B U.S. annual market with a $5B catch-up market opportunity

**Transplant Rejection/Mortality:**

- CMV is also a leading cause of transplant rejection in both the solid organ transplant and the stem-cell transplant settings
- Over 100,000 individuals in the U.S. are on the waiting list to receive a solid-organ transplant
- Matching based on CMV sero-status is not practical given other constraints (e.g. timely organ supply)
- Despite anti-viral pretreatment, CMV status of both recipient and donor still has a major impact on organ and recipient survival
Summary of Phase I Study Results

Phase I Study in 128 CMV-Negative Healthy Adults (18-40 years)

- VBI-1501 is safe and well tolerated at all doses tested, with and without the adjuvant alum, with no concern about evaluating VBI-1501A at higher doses

- VBI-1501A is immunogenic, even at a low dose
  - gB antibody binding titers induced at all dose levels, with clear evidence of dose-dependent boosting after each vaccination
  - Neutralizing antibodies against fibroblast cell infection were comparable to those from CMV-positive controls in 100% of subjects receiving the highest dose
  - Neutralizing antibodies against epithelial cell infection had a correlation with higher gB binding titers and fibroblast cell neutralizing activity, suggesting the modified form of the gB-G used in VBI-1501A qualitatively enriches for functional nAb activity
  - Highest dose tested (2.0μg) is 1/10th that of several other licensed VLP-based vaccines and past non-VBI CMV candidates

- There is strong scientific rationale to support that higher doses of VBI-1501A could improve the immunogenicity and efficacy
Summary
VBI Vaccines Leadership

**MANAGEMENT**

- Jeff Baxter  
  President & CEO
- Dr. David Anderson, Ph.D.  
  Chief Scientific Officer
- Dr. Francisco Diaz-Mitoma, M.D., Ph.D.  
  Chief Medical Officer
- Chris McNulty  
  Chief Financial Officer
- Nell Beattie  
  Chief Business Officer
- Avi Mazaltov  
  Global Head of Manufacturing  
  SciVac General Manager

**BOARD OF DIRECTORS**

- Dr. Steve Gillis, Ph.D.  
  Chairman
- Damian Braga
- Joanne Cordeiro
- Dr. Michel De Wilde, Ph.D.
- Blaine H. McKee, Ph.D.
VBI Vaccines Global Footprint

HEADQUARTERS – CAMBRIDGE, MA
- CEO, CSO, CFO, CBO + 3 FTEs
- Central location in biotechnology hub

RESEARCH OPERATIONS – OTTAWA, CANADA
- CMO, Finance + ~25 FTEs
- R&D team and facility

MANUFACTURING FACILITY – REHOVOT, ISRAEL
- ~80 FTEs
- GMP manufacturing facility for the production of Sci-B-Vac®
Summary

ANTICIPATED CATALYSTS THROUGH 2020 YEAR-END:

1. **Sci-B-Vac®: Hepatitis B Prophylactic Vaccine**
   - **Q2 2020** – Pre-BLA discussion expected with FDA
   - **Q4 2020** – Submissions of applications for regulatory approvals in the U.S., Europe, and Canada expected to begin

2. **VBI-1901: GBM Vaccine Immunotherapeutic (Immuno-Oncology)**
   - **Mid-year 2020** – Expanded immunologic data, tumor and clinical responses expected from VBI-1901 + GM-CSF Phase IIa study arm
   - **Q4 2020** – Initial immunologic data expected from VBI-1901 + AS01b Phase IIa study arm

3. **VBI-2601: Hepatitis B Immunotherapeutic**
   - **H2 2020** – Initial human proof-of-concept Phase Ib/Ila data readout expected